Jiaxin Niu is an Oncology physician affiliated with Banner Health. OpenAlex indexes 153 publications with 3,935 citations (h-index 22); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2946 E Banner Gateway Dr
Gilbert, AZ 852342165
Telephone
480-256-6444Registry record last updated 7 Aug 2025.
Clinical trials
- Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
Sponsor: Western Regional Medical Center
- Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
Sponsor: Western Regional Medical Center
- Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Sponsor: Western Regional Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- Daiichi Sankyo Inc.Program year202512 payments
- Novocure Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
23.7%Corticosteroid11.2%Prednisone100%Part D≥92 patientsSerotonin-3 Receptor Antagonist8.2%Ondansetron Hcl100%Part D≥80 patients+ 2 more classes in this area
Nervous system
20.2%Gabapentinoids8%Gabapentin84%Pregabalin16%Part D<11 patientsOpioid Agonist5.2%Tramadol Hcl46%Oxycodone-Acetaminophen35%Methadone Hcl19%Part D<11 patients+ 5 more classes in this area
Cancer & immunology
16.6%Kinase inhibitor14.2%Tagrisso38%Alecensa27%Mekinist12%Tafinlar9%Retevmo7%Tabrecta7%Part D<11 patientsAromatase Inhibitor1.5%Anastrozole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Journal of Clinical Oncology
2025 - Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Nakaji, MD
Banner Health
David Shprecher, DO
Banner Health
David Rizik, MD
Banner Health
Kelly Krohn, MD
Banner Health
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”